---
category: trading
circular_id: 1edd08d10b010095
date: '2025-12-30'
description: NSE enables trading of Rights Entitlements (REs) for Vineet Laboratories
  Limited from January 01, 2026 to January 16, 2026 in Trade to Trade segment.
draft: false
guid: https://nsearchives.nseindia.com/content/circulars/CML72061.pdf
impact: medium
impact_ranking: medium
importance_ranking: medium
justification: Affects shareholders of Vineet Laboratories Limited who may participate
  in rights issue through trading of REs during specified period
pdf_url: https://nsearchives.nseindia.com/content/circulars/CML72061.pdf
processing:
  attempts: 1
  content_hash: 8fbb6c41432d177e
  processed_at: '2025-12-30T15:33:02.354541'
  processor_version: '2.0'
  stage: completed
  status: published
published_date: '2025-12-30T00:00:00+05:30'
rss_url: https://nsearchives.nseindia.com/content/circulars/CML72061.pdf
severity: medium
source: nse
stocks:
- VINEET
tags:
- rights-issue
- rights-entitlements
- trading
- trade-to-trade
- renunciation
- compulsory-demat
title: Trading of Rights Entitlements pursuant to Rights Issue of Vineet Laboratories
  Limited
---

## Summary

NSE has admitted Rights Entitlements (REs) of Vineet Laboratories Limited for trading on the Capital Market segment effective January 01, 2026. The REs will trade under symbol VINEET-RE (ISIN: INE505Y20010) in the Trade to Trade segment with compulsory demat mode. A total of 9,983,235 Rights Entitlements will be available for trading and renunciation from January 01, 2026 to January 16, 2026, with suspension of trading on January 19, 2026.

## Key Points

- Trading symbol: VINEET-RE
- ISIN: INE505Y20010
- Series: BE (Trade to Trade segment)
- Total Rights Entitlements: 9,983,235
- Market lot: 1
- Compulsory demat for all investors
- REs must not be mistaken for ordinary shares of the company
- Trading members must inform clients about commencement of trading in REs
- Contract notes must include disclaimer about RE purchases

## Regulatory Changes

No new regulatory changes introduced. This circular implements existing regulations under NSE (Capital Market) Trading Regulations Part A, specifically Regulation 3.1.1 for admission of securities and Regulation 2.5.5 for lot size specification.

## Compliance Requirements

**For Trading Members:**
- Inform all clients about commencement of trading in REs
- Clearly mention the ISIN of the RE (INE505Y20010)
- Include prominent disclaimer in contract notes/bills for RE purchases
- Disclaimer must inform clients that:
  - Purchase of REs gives right to participate in ongoing Rights Issue by making application with requisite money OR renounce REs before issue closes
  - REs neither subscribed nor renounced on or before Issue Closing Date shall lapse and be extinguished after Issue Closing Date

**For Investors:**
- REs can only be traded in demat form (compulsory demat)
- Must take action before Issue Closing Date to either subscribe or renounce

## Important Dates

- **Effective Date:** January 01, 2026
- **Trading Period Start:** January 01, 2026
- **Trading Period End (Renunciation):** January 16, 2026
- **Suspension Date:** January 19, 2026
- **Issue Closing Date:** Not specified in circular (before January 19, 2026)

## Impact Assessment

**For Shareholders:**
Existing shareholders of Vineet Laboratories Limited can trade their Rights Entitlements in the secondary market during the 16-day trading window. This provides liquidity and flexibility to monetize rights without subscribing to the issue.

**Market Impact:**
Limited to shareholders and investors interested in Vineet Laboratories Limited rights issue. Trade to Trade segment classification indicates stricter settlement requirements with no intraday trading allowed. The compulsory demat requirement ensures transparent and traceable transactions.

**Operational Impact:**
Trading members need to update systems for the new security code and ensure proper client communication and disclaimer inclusion in contract notes. The market lot of 1 allows granular trading of rights entitlements.